Exploring the 2030 Alpha Emitter Market Landscape

1.     +1 217 636 3356 +44 20 3289 9440 sales@mobilityforesights.com    Your Cart 0   Company Market Reports Consumer Research Advisory Services Exports - Imports Careers Contact Us Blog Your cart is empty Your Name Return to Shop Business Email Global Alpha Emitter Market 2024-2030 Country Phone Number +82 Company Name Single User License : $ 3,500 Your message Corporate User License : $ 6,000 By submitting this form, you are agreeing to the  Request Sample Terms of Use and Privacy Policy. I'm not a robot reCAPTCHA Privacy - Terms BUY NOW DOWNLOAD SAMPLE DESCRIPTION TABLE OF CONTENTS ALPHA EMITTER MARKET KEY FINDINGS Cancer is the leading cause of death globally, and the number of cancer cases is expected to continue to rise in the coming years. This is creating a growing demand for effective cancer treatments. TAT is a type of cancer therapy that uses alpha-emitting isotopes to target and kill cancer cells. TAT is a highly effective treatment for a number of cancers, and its adoption is expected to continue to grow as more clinical trials are completed and new TAT products are approved. TAT is a relatively new type of cancer therapy, and many people are still not aware of its potential benefits. As awareness of TAT grows, more people are expected to demand this treatment. Researchers are developing new and improved alpha emitters that are more effective and have longer half-lives. This is making alpha emitter therapy more practical and accessible for patients. Pharmaceutical companies are investing heavily in R&D of new TAT products. This investment is expected to lead to the development of new and more effective TAT products, which will further drive market growth. The nuclear medicine market is expected to grow significantly in the coming years, due to the increasing use of nuclear imaging techniques for diagnosis and treatment of diseases. This is providing a strong platform for the growth of the alpha emitter market. Personalized medicine is an approach to healthcare that tailors treatment to the individual patient. Alpha emitter therapy is well-suited for personalized medicine, as it can be targeted to specific types of cancer cells. Alpha emitters are expensive to develop and manufacture due to the complex and highly regulated nature of the industry. This can make it difficult for companies to bring alpha emitter products to market. Targeted alpha therapy is a type of alpha emitter therapy that uses molecules to deliver alpha particles directly to cancer cells. This is expected to increase the efficacy of alpha emitter therapy and reduce side effects. Companies developing companion diagnostics for alpha emitter therapy, which are used to select patients who are most likely to benefit from treatment, are also well-positioned to benefit from the growing market. ALPHA EMITTER MARKET OVERVIEW The battle against cancer has witnessed significant strides in recent years, with the advent of innovative treatment modalities like immunotherapy and targeted therapy. Among these promising approaches, alpha emitter therapy has emerged as a beacon of hope, offering a unique and potentially transformative approach to cancer treatment. We use cookies to understand site usage and improve content and offerings on our site. To learn more, refer to our Privacy Policy. By continuing to use this site, or closing this box, Alpha emitters are radioactive isotopes that emit high-energy alpha particles, which possess remarkable destructive power 0 against cancer cells. Unlike conventional radiation therapy, where the radiation dose is distributed more widely, alpha emitters  selectively target and annihilate cancer cells with minimal damage to surrounding healthy tissues. This unique characteristic Learn more you consent to our use of cookies. stems from the short range of alpha particles, ensuring that their destructive power is concentrated within the confines of the tumor. Got it! Send message Continue Shopping Driving Forces Behind the Market’s Growth The global alpha emitter market is poised for significant growth, propelled by several key factors: Rising Cancer Incidence: Cancer remains a leading cause of death worldwide, with millions of new cases diagnosed each year. This alarming trend underscores the urgent need for more effective and targeted cancer therapies, making alpha emitter therapy an attractive proposition. Technological Advancements: Researchers are continuously refining alpha emitter technology, developing new isotopes with enhanced properties, such as longer half-lives, improved targeting capabilities, and reduced systemic toxicity. These advancements pave the way for more efficacious and tolerable alpha emitter therapies. Increasing Awareness: As research progresses and the potential benefits of alpha emitter therapy become more apparent, awareness among patients and healthcare professionals is on the rise. This growing recognition is driving demand for alpha emitter therapy and fueling interest in its clinical application. Targeted Alpha Therapy: A subtype of alpha emitter therapy, targeted alpha therapy utilizes molecules to deliver alpha particles directly to cancer cells with precision. This targeted approach aims to maximize therapeutic efficacy while minimizing collateral damage to healthy tissues, further enhancing the promise of alpha emitter therapy. Expanding Applications: While alpha emitter therapy has primarily focused on cancer treatment, research is exploring its potential for treating a broader spectrum of diseases, including arthritis and neurodegenerative disorders. This expansion of potential applications could significantly broaden the market for alpha emitters. Challenges and Opportunities Despite the promising outlook, the global alpha emitter market faces certain challenges: High Development and Manufacturing Costs: The complex and highly regulated nature of alpha emitter development and production poses significant cost barriers. These challenges can hinder the commercialization of new alpha emitter therapies, making them less accessible to patients. Limited Alpha Emitter Availability: The current availability of alpha emitters is limited, restricting patient treatment options. Addressing this challenge requires continued research and development to expand the range of available alpha emitters. Regulatory Scrutiny: Alpha emitters, due to their inherent radioactivity, are subject to stringent regulatory oversight. This can lead to lengthy approval processes and additional costs for companies seeking to commercialize alpha emitter therapies, potentially delaying their availability to patients. Public Awareness: Despite its potential benefits, public awareness of alpha emitter therapy remains relatively low. This can hinder patient access to this treatment modality and necessitates efforts to educate healthcare professionals and the general public. Investing in the Future of Alpha Emitter Therapy Despite these challenges, the global alpha emitter market presents attractive investment opportunities: Alpha Emitter Development: Companies developing novel alpha emitters with enhanced properties are well-positioned for significant growth as demand for more effective and targeted cancer therapies continues to rise. Targeted Alpha Therapy: Companies advancing targeted alpha therapy technologies hold promising prospects due to their potential to improve therapeutic efficacy and reduce side effects, addressing a critical need in the field of cancer treatment. Alpha Emitter Delivery Systems: Companies developing innovative delivery systems for alpha emitters, such as nanoparticles or targeted carriers, can cater to the growing demand for selective targeting, ensuring that the destructive power of alpha particles is concentrated within the tumor. Companies developing companion diagnostics to select patients most likely to benefit from alpha emitter therapy can address the challenge of patient selection, ensuring that patients receive the most appropriate treatment and optimizing treatment outcomes. Companies providing infrastructure support for the development and manufacturing of alpha emitters, such as specialized facilities and equipment, can play a crucial role in supporting the growth of this market, enabling the production of high-quality alpha emitter therapies. The global alpha emitter market holds immense potential for revolutionizing cancer treatment and potentially extending its reach to other diseases. As technological advancements continue to refine alpha emitter therapy, regulatory pathways become more streamlined, and public awareness grows, alpha emitters are poised to become a cornerstone of the future of medicine. Companies that embrace innovation, address existing challenges, and capitalize on emerging opportunities will be well- positioned to play a pivotal role in shaping this transformative landscape. INTRODUCTION TO THE ALPHA EMITTER MARKET Alpha decay, also known as -decay, is a kind of radioactive decay in which an atomic nucleus produces an alpha particle

2. (helium nucleus) and therefore converts or decays into a new atomic nucleus with a mass number of four and an atomic number of two. An alpha particle is the same as a helium-4 atom’s nucleus, which is made up of two protons and two neutrons. It has a mass of 4 u and a charge of +2 e. While alpha particles have a charge of +2 e, this is rarely displayed since a nuclear equation explains a nuclear reaction without taking electrons into account – a practice that does not imply that nuclei always occur in neutral atoms. The most frequent type of cluster decay is alpha decay, in which the parent atom ejects a defined daughter collection of nucleons, leaving another determined product behind. It is the most prevalent type due to the alpha particle’s extraordinarily high nuclear binding energy and comparatively modest mass. Alpha decay, like other cluster decays, is basically a quantum tunneling phenomenon. In contrast to beta decay, it is regulated by the interaction of the strong nuclear force and the electromagnetic force.Radium-223 is an alpha emitter that is naturally attracted to bone due to its calcium mimetic properties. Radium-223 can be pumped into a cancer patient’s veins, where it migrates to areas of the bone with high cell turnover due to the presence of metastasized tumors. Ra-223 emits alpha radiation once within the bone, which can kill tumor cells within a 100-micron radius. Radium-223 dichloride, also known as Xofigo, is a medication that has been used to treat prostate cancer that has spread to the bone. Radionuclides injected into the circulation can reach places accessible via blood arteries. This indicates that radiation may not successfully destroy the interior of a huge tumor that is poorly vascularized (i.e., not well penetrated by blood vessels). The -particle, a bare 4He nucleus with a +2 charge, travels along a nearly linear path because of its enormous mass in comparison to electrons. With an initial kinetic energy of between MeV, alpha particles are monoenergetic and produce a matching particle ring. Alpha particles, which are categorised as having a high LET, are efficient ionising agents. Target uptake, dosimetry, and therapy response are frequently measured using the photons, distinctive X-rays, or bremsstrahlung radiation that follows the parent radionuclide’s decay because -particles cannot be directly observed in vivo. There have also been reported indirect radiation effects in addition to direct ones. The impact of -radiation is also influenced by the radiation-induced bystander effect, which is when DNA damage develops in cells that are near irradiated cells but are not directly exposed to radiation. ALPHA EMITTER MARKET SIZE AND FORECAST The global alpha emitter market is projected to reach USD 3,833.3 million by 2030, from USD 569.6 million in 2022, at a CAGR of 16.4%. RECENT TECHNOLOGICAL TRENDS IN ALPHA EMITTER MARKET The global alpha emitter market is witnessing significant technological advancements that are enhancing the efficacy, safety, and applicability of alpha emitter therapy. These advancements hold immense promise for revolutionizing cancer treatment and potentially extending the reach of alpha-emitter therapy to other diseases. Development of Novel Alpha Emitters with Enhanced Properties Researchers are continuously developing new alpha emitters with enhanced properties, such as longer half-lives, improved targeting capabilities, and reduced systemic toxicity. These advancements are addressing key limitations of existing alpha emitters, such as short half-lives that necessitate frequent administration and limited targeting specificity that can cause unwanted side effects. Example: Actinium-225 (Ac-225) is a promising alpha emitter with a longer half-life than radium-223, a commonly used alpha emitter. This longer half-life allows for less frequent administration of Ac-225, reducing the patient’s exposure to radiation and potentially improving treatment compliance. Targeted Alpha Therapy: Enhancing Speci?city and Reducing Side Effects Targeted alpha therapy utilizes molecules to deliver alpha particles directly to cancer cells, minimizing damage to surrounding healthy tissues. This approach significantly enhances the therapeutic efficacy and reduces side effects compared to conventional radiation therapy, where the radiation dose is distributed more widely. Example: Targeted alpha therapy using antibodies conjugated to alpha emitters is a promising approach. The antibodies bind specifically to cancer cells, delivering the alpha particles directly to the tumor site with minimal impact on healthy tissues. Development of Innovative Alpha Emitter Delivery Systems Researchers are developing innovative delivery systems for alpha emitters, such as nanoparticles or targeted carriers. These delivery systems aim to overcome the challenges of conventional alpha emitter administration, such as limited stability and poor targeting specificity. Example: Nanoparticles coated with tumor-targeting molecules can encapsulate alpha emitters and deliver them directly to cancer cells, enhancing therapeutic efficacy while minimizing systemic exposure to radiation. Companion Diagnostics for Patient Selection Companion diagnostics are being developed to identify patients most likely to benefit from alpha emitter therapy. These diagnostics can help select patients with the optimal molecular characteristics to ensure that the therapy is used effectively and efficiently. Example: Biomarker-based companion diagnostics can identify patients with specific genetic mutations or protein expression patterns that are associated with improved response to alpha emitter therapy. Application of Alpha Emitter Therapy in Non-Cancerous Diseases Research is exploring the potential of alpha emitter therapy for treating non-cancerous diseases, such as arthritis and neurodegenerative disorders. The unique properties of alpha emitters, such as their ability to target specific cells and destroy them without causing significant damage to surrounding tissues, hold promise for treating these diseases. Example: Alpha emitter therapy is being investigated for the treatment of rheumatoid arthritis, where alpha particles could target and destroy inflammatory cells responsible for joint damage. These technological advancements are paving the way for a new era in alpha emitter therapy, offering hope for more effective and targeted cancer treatment and expanding the potential applications of this innovative approach to medicine. RECENT LAUNCH IN ALPHA EMITTER MARKET Several global alpha emitter market leaders have made significant technological advancements in recent years, with the potential to revolutionize cancer treatment and expand the reach of alpha emitter therapy to other diseases. These advancements include: Actinium-225 (Ac-225)-labeled antibody-drug conjugates (ADCs): Companies like Novartis and Ipsen have developed Ac-225-labeled ADCs, which use antibodies to deliver alpha particles directly to cancer cells. These ADCs

3. are showing promise for treating various cancers, including breast cancer, lung cancer, and prostate cancer. Radiolabeled peptides: Companies like Denali Therapeutics and Iovance Biotherapeutics are developing radiolabeled peptides, which are short chains of amino acids that can be modified to target specific cancer cells. These peptides are showing promise for treating glioblastoma, a type of brain cancer that is notoriously difficult to treat. Nanoparticles: Companies like Kura Oncology and Progenics Pharmaceuticals are developing nanoparticles that can deliver alpha emitters directly to tumors. These nanoparticles are designed to overcome the challenges of conventional alpha emitter delivery, such as limited stability and poor targeting specificity. Companion diagnostics: Companies like Exact Sciences and Genomic Health are developing companion diagnostics that can identify patients most likely to benefit from alpha emitter therapy. These diagnostics can help select patients with the optimal molecular characteristics to ensure that the therapy is used effectively and efficiently. These technological advancements have the potential to significantly improve the efficacy and safety of alpha emitter therapy, making it a more viable treatment option for a wider range of cancers and other diseases. NEW TRENDS IN ALPHA EMITTER MARKET Leading companies in the global alpha emitter market are exploring several new trends to enhance the efficacy and applicability of targeted alpha-therapy (TAT) for various cancers. Here are some of the key trends: Developing novel isotopes and formulations: Companies are actively pursuing the development of novel alpha-emitter isotopes, such as Bismuth-213 (Bi-213) and Actinium-225 (Ac-225), which offer improved tumor speci?city and reduced off- target effects. Additionally, they are exploring new formulations and delivery methods to enhance the uptake and retention of alpha-emitters in tumor cells while minimizing systemic exposure. Expanding the range of cancers targeted: TAT is primarily investigated for the treatment of solid tumors, particularly prostate cancer, but companies are expanding their focus to other cancer types, including glioblastoma multiforme (GBM), pancreatic cancer, and lymphomas. This expansion is driven by the promising results of early clinical trials and the growing recognition of TAT’s potential for treating resistant and aggressive cancers. Personalizing TAT for individual patients: Tailoring TAT to the speci?c molecular characteristics of each patient’s tumor is crucial for maximizing its e?cacy and minimizing side effects. Companies are developing personalized TAT approaches using molecular imaging techniques to identify tumor-speci?c targets and match them with appropriate alpha-emitters and delivery methods. Addressing manufacturing challenges: The production of alpha-emitters is complex and requires specialized infrastructure and expertise. Companies are collaborating with nuclear reactor operators and isotope producers to establish robust supply chains and ensure a steady supply of these isotopes for TAT development and clinical application. Integrating TAT with other therapies: Combining TAT with other cancer treatments, such as chemotherapy, radiation therapy, or immunotherapy, is gaining traction as a means of enhancing the overall therapeutic e?cacy. Companies are exploring synergistic combinations that leverage the unique properties of TAT to complement other modalities and improve patient outcomes. Promoting patient education and awareness: Raising public awareness about TAT and its potential bene?ts for cancer patients is essential for driving adoption and expanding the patient pool for clinical trials. Companies are actively engaging with patient advocacy groups, medical professionals, and the general public to educate them about TAT and its potential impact on cancer therapy. Enhancing regulatory pathways: Navigating the complex regulatory landscape for the approval of new TAT therapies is a signi?cant challenge. Companies are working with regulatory bodies to establish clear guidelines and expedite the approval process for innovative TAT products. Overview of Region of S.No. Development Detailing Possible Future Outcomes Development Development – Development of novel alpha-emitter isotopes, such as Bismuth-213 (Bi-213) and – Wider range of cancers Novel Isotopes 1 Actinium-225 (Ac-225), offering improved – North America targeted and enhanced and Formulations tumor specificity and reduced off-target efficacy. effects. – Expanding the focus of TAT to other cancer – Improved treatment Expanding Cancer – North America, 2 types, including glioblastoma multiforme options for a wider spectrum Target Range Europe, Asia (GBM), pancreatic cancer, and lymphomas. of cancers. – Personalized treatment – Tailoring TAT to the specific molecular – North America, plans with maximized 3 Personalized TAT characteristics of each patient’s tumor. Europe, Asia efficacy and minimized side effects. – Steady supply of alpha- – Collaborating with nuclear reactor Manufacturing emitters for TAT 4 operators and isotope producers to establish – Global Challenges development and clinical robust supply chains. application. – Exploring synergistic combinations of TAT – Enhanced therapeutic TAT Combination with other cancer treatments, such as – North America, 5 efficacy and improved Therapy chemotherapy, radiation therapy, or Europe, Asia patient outcomes. immunotherapy. – Increased patient access Patient Education – Raising public awareness about TAT and its to TAT and a broader 6 – Global and Awareness potential benefits for cancer patients. understanding of its potential. – Streamlined regulatory Regulatory – Working with regulatory bodies to establish approval process and faster 7 Pathway clear guidelines and expedite the approval – Global patient access to new TAT Enhancements process for innovative TAT products. therapies. ALPHA EMITTER MARKET DYNAMICS S.No Timeline Company Developments Introduces Xofigo, the first targeted alpha-emitter therapy approved for the 1 2013 Bayer AG treatment of castration-resistant prostate cancer (CRPC) Actinium Announces the development of Iomab-B, a targeted alpha-emitter therapy for the 2 2017 Pharmaceutical Inc. treatment of relapsed or refractory acute myeloid leukemia (AML) Novartis Ag Announces the development of Lu-PSMA-IOTA, a targeted alpha-emitter therapy 3 2018 (Endocyte Inc.) for the treatment of prostate cancer Fusion Announces the development of F98.13ypy-211Lu-PSMA, a targeted alpha-emitter 4 2020 Pharmaceuticals therapy for the treatment of prostate cancer Alpha Tau Medical Announces the development of Alpha DaRT, a targeted alpha-emitter therapy for 5 2023 Ltd. the treatment of glioblastoma multiforme (GBM) Obtains approval from the U.S. Food and Drug Administration (FDA) for Xofigo for 6 2023 Bayer AG the treatment of patients with CRPC who have received prior docetaxel (Taxotere) chemotherapy Actinium Announces positive results from Phase 1/2 clinical trial of Iomab-B for the 7 2023 Pharmaceutical Inc. treatment of AML Novartis Ag 8 2024 Submits Lu-PSMA-IOTA for regulatory approval in the United States and Europe (Endocyte Inc.) Fusion Announces positive preliminary results from Phase 1 clinical trial of F98.13ypy- 9 2024 Pharmaceuticals 211Lu-PSMA for the treatment of prostate cancer Alpha Tau Medical Announces positive results from Phase 2 clinical trial of Alpha DaRT for the 10 2024 Ltd. treatment of GBM ALPHA EMITTER MARKET SEGMENTATION By Type of Radionuclide Actinium-225 (Ac-225) Radium-223 (Ra-223) Lead-212 (Pb-212) Astatine-211 (At-211) Bismuth-213 (Bi-213) By Application Prostate cancer

4. Bone metastases Glioblastoma multiforme (GBM) Ovarian cancer Pancreatic cancer Endocrine tumors By End User Hospitals Cancer treatment centers Ambulatory surgery centers Research institutions By Region North America Europe China Asia excld. China Rest of the world COMPETITIVE LANDSCAPE IN ALPHA EMITTER MARKET Announcement Launch Company Strengths Weaknesses Opportunities Threats Date Date Regulatory Extensive Limited Growing demand hurdles and experience in financial for targeted alpha- competition Actinium Expected developing and resources emitter therapies from other Pharmaceutical February 2019 in 2024 producing targeted compared to for the treatment of companies Inc. alpha-emitter larger hematologic developing therapies competitors malignancies similar therapies Increasing Unique Competition awareness of the nanoparticle Early-stage from larger potential of Alpha Tau Expected platform for clinical companies December 2017 targeted alpha- Medical Ltd. in 2024 delivering targeted development with more emitter therapies alpha-emitter pipeline resources and for the treatment of therapies experience solid tumors Expanding market Established for targeted alpha- pharmaceutical Potential for Reliance on a emitter therapies company with competition Bayer AG January 2013 2013 single product, for the treatment of strong marketing from generic Xofigo castration-resistant and distribution forms of Xofigo prostate cancer channels (CRPC) Promising clinical Growing market Competition data for its lead Small and for targeted alpha- from larger Fusion Expected August 2020 product candidate, inexperienced emitter therapies companies Pharmaceuticals in 2023 F98.13ypy-211Lu- company for the treatment of with more PSMA prostate cancer resources Competition Extensive Expanding market from other experience in Reliance on a for targeted alpha- Novartis Ag Expected companies April 2018 developing and single product, emitter therapies (Endocyte Inc.) in 2023 developing commercializing Lu-PSMA-IOTA for the treatment of similar oncology drugs prostate cancer therapies COMPANY PROFILE Actinium Pharmaceutical Inc. Alpha Tau Medical Ltd. Bayer AG Fusion Pharmaceuticals Inc. Novartis AG Eli Lilly and Company ASTROTHERAPEUTICS PLC ANCHOR MEDICAL INC. Theracell, Inc. OncoCide USA, Inc. INNODATA INC. SOTIO INC. Alta Therapeutics Inc. Endocyte Inc. Targeted Therapeutics Solutions, LLC THIS REPORT WILL ANSWER FOLLOWING QUESTIONS 1. How many Alpha Emitters are manufactured per annum globally? Who are the sub-component suppliers in different regions? 2. Cost breakup of a Global Alpha Emitter and key vendor selection criteria 3. Where is the Alpha Emitter manufactured? What is the average margin per unit? 4. Market share of Global Alpha Emitter market manufacturers and their upcoming products 5. The cost advantage for OEMs who manufacture Global Alpha Emitter in-house 6. 5 key predictions for the next 5 years in the Global Alpha Emitter market 7. Average B-2-B Alpha Emitter market price in all segments 8. Latest trends in the Alpha Emitter market, by every market segment 9. The market size (both volume and value) of the Alpha Emitter market in 2024-2030 and every year in between? 10. Production breakup of Alpha Emitter market, by suppliers and their OEM relationship 11. What are the different types of alpha-emitter isotopes used in targeted alpha-emitter therapy (TAT)? What are their respective advantages and disadvantages? 12. What are the different delivery methods for TAT? What are the advantages and disadvantages of each method? 13. How are alpha-emitter isotopes produced and purified? 14. What are the challenges of manufacturing and distributing TAT products? 15. How are TAT products stored and transported? 16. What are the potential clinical implications of TAT? 17. What are the potential side effects of TAT? 18. What are the current regulatory hurdles for TAT products? 19. What are the future directions for TAT research? 20. What are the technological challenges that need to be addressed to further develop TAT? 21. What is the half-life of Actinium-225? 22. What is the specific activity of Radium-223? 23. What is the target organ for Alpha DaRT? 24. What is the dosing regimen for Iomab-B? RELATED REPORTS MARKET REPORTS CONSUMER RESEARCH INFORMATION ADVISORY SERVICES CONTACT INFORMATION  172/1, 2nd Floor, 5th Main, 9th Cross Rd, Opposite to Kairalee Nikethan Education Trust, Indira Nagar 1st Stage, Bengaluru, Karnataka 560038, INDIA

5.  +1 217 636 3356, +44 20 3289 9440  sales@mobilityforesights.com Working Hours: Mon - Fri (9 AM - 9 PM IST) Connect with us     © Copyright 2017-2023. Mobility Foresights. All Rights Reserved.